Top Story Today
Third FDA Commissioner in Three Years: Makary Is Out After 14 Months
The White House approved plans to remove FDA Commissioner Marty Makary after only 14 months on the job, though the plan has not yet been executed and could still change. The move would create the agency's third leadership change since 2024. Makary pushed through roughly 30 policy shifts (including a landmark single-trial approval framework) but managed to alienate Congress, industry, and his own staff simultaneously. No permanent successor has been named, and the interim period could last 4 to 8 months, historically adding 10-20% to approval timelines for companies with pending applications.
Why it matters: For biotech companies and investors, every FDA leadership vacuum translates directly into approval delays and regulatory uncertainty. With major reforms left unfinished and no confirmed replacement in sight, the industry faces months of autopilot at the worst possible time.
Read more →Clinical & Regulatory
Leqembi's At-Home Shortcut Hits a Three-Month FDA Roadblock
The FDA extended its review of Leqembi's subcutaneous starting dose by three months, pushing the decision to August 24. For a reformulation of an already-approved drug, that's unusual. The likely culprit: manufacturing complexity around the higher 500 mg concentration. Wall Street shrugged (reimbursement wouldn't kick in until 2027 anyway), but the delay keeps Alzheimer's patients tethered to infusion centers longer than planned.
Read more →enGene's Bladder Cancer Drug Works, Just Not Well Enough to Matter
enGene's stock lost 80% in a single day after its bladder cancer therapy posted a 54% response rate, well behind J&J's 82% and CG Oncology's 75.5%. Multiple analysts downgraded within hours. Leerink slashed peak sales estimates from $1 billion to $350 million. The drug may still get approved, but in oncology, "approvable" and "commercially viable" are very different things.
Read more →Deals & Capital Markets
Roche Pays $1 Billion for an AI Pathologist That Never Blinks
Roche is acquiring PathAI for up to $1.05 billion ($750M upfront, $300M in milestones), adding AI-powered slide analysis to its diagnostics empire. PathAI works with 90% of the top 15 biopharma companies and already holds FDA clearance for primary diagnosis. The deal slots into Roche's broader AI infrastructure, which now includes over 3,500 GPUs dedicated to drug discovery and diagnostics.
Read more →Two Biotechs Raised $556M in Back-to-Back IPOs, Both Upsized
Hemab (rare bleeding disorders) raised $301.5M at initial pricing and Seaport Therapeutics (neuropsychiatry) pulled in $255M to become 2026's first neuro-focused IPO. Both upsized due to overwhelming demand. After 2025's historic drought, Q1 2026 alone saw six biopharma IPOs raise $1.8 billion, topping the entire prior year.
Read more →Science & Discovery
A Liver Gene Therapy Cleared Brain Amyloid in Mice (Yes, the Liver)
Chinese researchers delivered the protective APOE3 Christchurch gene to mouse livers and watched amyloid plaques shrink in their brains. The trick: supercharging the blood's ability to clear amyloid pulls it out of the brain like draining a connected pool from below. No blood-brain barrier crossing required. It's a mouse study (big caveat), but the conceptual shift from brain-first to periphery-first could reshape Alzheimer's drug development.
Read more →